Search
Pergolide
go.drugbank.com/drugs/DB01186ApprovedVet approvedWithdrawnThe drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. … While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes.
Products: PERGOLIDE EG, PERGOLID-NEURAX 1 MGTravoprost
go.drugbank.com/drugs/DB00287ApprovedInvestigationalIt is used to decrease intraocular pressure in open-angle glaucoma and ocular hypertension. … [L49434] Unlike other prostaglandin analogues, travoprost demonstrates full agonism and high selectivity at the prostanoid receptor, reporting a higher efficacy in reducing intraocular pressure and a reduced
Mixtures: TRAVOPROST E TIMOLOLO EG, TRAVOPROST E TIMOLOLO EGSynonyms: -TRIFLUORO-M-TOLYL)OXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOATE, isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoateDexrazoxane
go.drugbank.com/drugs/DB00380ApprovedInvestigationalWithdrawn[PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. … It appears to inhibit formation of a toxic iron-anthracycline complex.
Categories: Compounds used in a research, industrial, or household settingProducts: Cyrdanax 20 mg/ml Pulver zur Herstellung einer InfusionslösungLixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).
Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, Soliqua SoloStar 100units/mL+50mcg/mL solution for injection in a pre-filled penCategories: Drugs Used in Diabetes, Receptors, G-Protein-CoupledLabetalol
go.drugbank.com/drugs/DB00598ApprovedInvestigational[L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Products: DUOBLOQ 100 MG / 20 ML, TELABELOL 100 MG/ 20 MLMedroxyprogesterone acetate
go.drugbank.com/drugs/DB00603ApprovedInvestigationalmanage pain in endometriosis, prevent pregnancy, and is also used in palliative care for endometrial and renal carcinoma. … [A14848] MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy,
Mixtures: DIVINA 2 MG + 2 MG /10 MG TABLET, 21 ADET, DIVICONT TABLETAS 1 MG/5 MGSynonyms: (6α)-17-(Acetyloxy)-6-methylpreg-4-ene-3,20-dioneChlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnMedications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. … Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites.
Categories: Drugs Used in DiabetesSynonyms: N-(4-chlorophenylsulfonyl)-N'-propylurea, N-(p-chlorobenzenesulfonyl)-N'-propylureaSelexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalcirculation and decrease elevated pressure in the blood vessels supplying blood to the lungs. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary
Products: UPTRAVI 200 MCG, UPTRAVI 200 MCG FILM KAPLI TABLET, 60 ADETLornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam is approved for use in Japan. … Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug.
Mixtures: LORNOPAR 8/300 MG EFERVESAN TABLET ,20 ADETProducts: XEFO 4 MG FILM KAPLI TABLET, 20 ADET, XEFO 8 MG FILM KAPLI TABLET, 20 ADETAlbutrepenonacog alfa
go.drugbank.com/drugs/DB13884ApprovedIt is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305] … [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016.
Products: IDELVION 2000 IU powder and solvent for solution for injection, ไอเดลวิออน 250